Single Doses of the Glucokinase Activator Ly2608204 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2dm).
Phase of Trial: Phase I
Latest Information Update: 25 Mar 2013
At a glance
- Drugs LY 2608204 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 25 Mar 2013 New trial record
- 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.